The Effects of Different Doses of Submucosal vs. Intravenous Ketamine for Conscious-sedation in Children Candidates for Diagnostic-Therapeutic Procedures in Emergency Department
Introduction: Ketamine is a commonly used medicine for reducing pain and stress in patients, including children in emergency department (ED). The intravenous (IV) injection of ketamine is gold standard though difficult in children, but other routes are also possible. Objective: This study was conducted to compare the effects of the submucosal at different doses versus IV injections of ketamine on sedation with proper consciousness in children candidates for diagnostic-therapeutic procedures in ED. Methods: This randomized clinical trial was conducted with 4 groups; groups 1, 2 and 3 respectively received 4, 3 and 2 mg/kg of submucosal ketamine and group four 1.5 mg/kg of IV ketamine. Eligible subjects selected from 46 patients of children’s age as the candidates for subcutaneous wound healing were randomly assigned to the four groups and followed up 5, 10, 15 and 30 minutes after the injection. The Ramsay score was obtained by measuring the heart rate, the breathing rate, the time to start affecting and duration of the effect. The data were ultimately analyzed in SPSS and Excel. Results: The baseline data were matched and confounding variables eliminated included age, gender, weight and hemodynamics. Compared to other doses of submucosal ketamine, 4 mg/kg was found to exert its effect the fastest (4.08±1.01 minutes) (p<0.05) and for the longest duration (23.09±1.12 minutes) (p<0.05). The Ramsay score in groups 1 and 4, i.e. 5.9, was significantly higher than that in groups 2 and 3 (p<0.05). Conclusions: The results showed that 4 mg/kg and 3 mg/kg of submucosal ketamine are appropriate alternatives to IV ketamine. Although the time to start affecting was shorter in the intravenous group compared to in the other groups, the duration of the effect was the longest with 4 mg/kg of submucosal ketamine. Surgeon satisfaction scores were found to be very good and not significantly different between groups 1, 2 and 4. Vomiting was also prevalent with no significant differences between the four groups.
2. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370-80.
3. Tadrisi S, Madani S, Farmand F, Ebadi A, Karimi ZA, Saghafinia M, et al. Richmond Agitation-Sedation Scale Validity and Reliability in Intensive Care Unit Adult Patients; Persian Version. Crit Care Nurs. 2009;2(1):15-21.
4. Botha JA, Mudholkar P. The effect of a sedation scale on ventilation hours, sedative, analgesic and inotropic use in an intensive care unit. Crit Care Resusc. 2004;6(4):253-7.
5. Weisbrodt L, McKinley S, Marshall AP, Cole L, Seppelt IM, Delaney A. Daily interruption of sedation in patients receiving mechanical ventilation. Am J Crit Care. 2011;20(4):e90-8.
6. Kennedy RM, McAllister JD. Midazolam with ketamine: who benefits? : Elsevier; 2000.
7. Proudfoot J. Analgesia, anesthesia, and conscious sedation. Emerg Med Clin N Am. 1995;13(2):357-79.
8. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989;36(2):186-97.
9. Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28(6):536-44.
10. Dilley JD, Gentry WB, Golden KJ, Culp WC. Ketamine infusion as a treatment for major depressive disorder: A new role for anesthesiologists? Middle East J Anaesthesiol. 2012;21(6):871-3.
11. Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacol. 2015;40(5):1084-90.
12. Roberts JR, Hedges JR. Roberts and Hedges’ Clinical Procedures in Emergency Medicine E-Book: Elsevier Health Sciences; 2013.
13. Majidi S, Parna A, Zamani M, Akhbari K. Onset and Effect Duration of Intrabuccal Space and Intramuscular Ketamine in Pediatrics. Adv Biomed Res. 2018;7(1):91.
14. Momeni M, Esfandbod M, Saeedi M, Farnia M, Basirani R, Zebardast J. Comparison of the effect of intravenous ketamine and intramuscular ketamine for orthopedic procedures in children's sedation. Int J Crit Illn Inj Sci. 2014;4(3):191-4.
15. Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet. 2006;367(9512):766-80.
16. Roback MG, Wathen JE, MacKenzie T, Bajaj L. A randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. Ann Emerg Med. 2006;48(5):605-12.
17. Majidi Nejad S, Goudarzi L, Heydari F. Effect of Ondansetron on the Incidence of Ketamine Associated Vomiting in Procedural Sedation and Analgesia in Children: A Double-Blind, Randomized, Placebo-Controlled Trial. Int J Pediatr. 2018;6(4):7511-8.
|Issue||Vol 5 No 1 (2021): Winter (February)|
|Administration, Buccal Children Conscious Sedation Drug Administration Routes|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|